Company Profile
Grindeks Stock Price, News & Analysis
- Ticker:
- GRD1R
- Exchange:
- AMEX
- Sector:
- Biopharma
- Location:
- Latvia and operates as a pharma manufacturer and marketer
Why the stock is moving
Current closing-price context is not available for GRD1R.
Company overview
Business overview
Grindeks is a pharmaceutical company focused on generic and specialty medicines with a strong regional manufacturing and commercialization base. Its business is rooted in drug production rather than biotech innovation.
Geographic Base and Sector Classification
Grindeks is headquartered in Latvia and operates as a pharma manufacturer and marketer. It belongs to pharmaceuticals rather than biotech.
Business Model Characteristics
The company depends on manufacturing execution, product sales, and regional market access. Investors watch revenue growth, export reach, and portfolio stability.
Position Within the Biotechnology Landscape
Grindeks sits in the generic/specialty-pharma category rather than biotech. Its movement is more about commercial manufacturing and market access than clinical catalysts.
Future catalysts
Grindeks is not a live U.S. biotech catalyst name in the same way as the others, so the best fit is to treat it as a legacy / non-core listing with no meaningful near-term U.S.-style catalyst. The stock is mainly a structural or market-access name.
Recent news
The five most recent related feed items are shown below in reverse chronological order.
- 01
Amneal Expands Iohexol Injection Portfolio with U.S. FDA Approval of Additional Strengths and Presentations
AMRX · Source: Amneal Pharmaceuticals
- 02
Amneal to Report Second Quarter 2026 Results on July 30, 2026
AMRX · Source: Amneal Pharmaceuticals
- 03
Teva and Polpharma Biologics Announce Global Licensing Agreement for a Biosimilar Candidate to Ocrevus® (ocrelizumab) for Multiple Sclerosis
TEVA · Source: Teva Pharmaceutical Industries
- 04
Amneal and Adalvo Announce FDA Acceptance for Review of Two U.S. ANDAs for Generic Tirzepatide Autoinjector
AMRX · Source: Amneal Pharmaceuticals
- 05
Teva to Advance Its Anti-IL-15 Antibody, Designed for Quarterly Dosing, Into Phase 2b Development in Vitiligo, Following Encouraging Phase 1b Results
TEVA · Source: Teva Pharmaceutical Industries
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What does Grindeks do?
Grindeks is a pharmaceutical company focused on generic and specialty medicines with a strong regional manufacturing and commercialization base. Its business is rooted in drug production rather than biotech innovation.
On which exchange is GRD1R stock listed?
Grindeks (GRD1R) is associated with AMEX, Latvia and operates as a pharma manufacturer and marketer, Biopharma.
What is Grindeks?
Grindeks is not a live U.S.
Which conditions is Grindeks targeting with Grindeks?
Grindeks is not a live U.S.
How does Grindeks describe recent progress with Grindeks?
Grindeks is not a live U.S.
What future catalysts are investors watching for Grindeks?
Grindeks is not a live U.S. biotech catalyst name in the same way as the others, so the best fit is to treat it as a legacy / non-core listing with no meaningful near-term U.S.-style catalyst. The stock is mainly a structural or market-access name.